



## Novel Approaches for Delivery of Anti-HIV Drugs

Guest Editor:

### Dr. José das Neves

1. i3S—Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal

2. INEB—Institute of Biomedical Engineering, University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal

3. CESPU—Institute for Research and Advanced Training in Health Sciences and Technologies, Rua Central de Gandra 1317, 4585-116 Gandra, Portugal

Deadline for manuscript submissions:

**closed (20 February 2019)**

### Message from the Guest Editor

Dear Colleagues,

HIV/AIDS is one of the most challenging public health concerns nowadays, affecting roughly 37 million individuals worldwide and killing nearly two million people each year according to the UNAIDS. Investments in the field have been huge but a cure to the infection remains elusive.

Many challenges remain in anti-HIV therapy/prophylaxis and these include, among others: (i) severe adverse effects; (ii) sub-optimal biodistribution and pharmacokinetics, particularly at reservoir sites or mucosae involved in sexual transmission; (iii) viral resistance; (iv) poor adherence due to troublesome regimens and/or drug delivery routes; (v) low stability/reduced shelf-life; (vi) lack of dosage forms for particular populations (e.g. children, women); (vii) costly drugs.

This Special Issue focuses on new strategies to the formulation and delivery of anti-HIV drugs (including genetic material and other biopharmaceuticals), which could help solving above identified issues. We welcome articles/reviews on all aspects of anti-HIV drug delivery targeting HIV/AIDS.

Dr. José das Neves





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma